BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Soluble Therapeutics, Inc. Awarded $1MM National Institutes of Health (NIH) Grant for Continued Development of the HSC Technology for Protein Formulation


7/23/2012 11:53:44 AM

Birmingham, AL – 1 June 1, 2012 – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO specializing in formulation optimization for protein-based therapeutics announces a Phase II award of approximately $1MM from the NIH Small Business Technology Transfer Program (STTR).

After closing a $1MM round of venture funding in the summer of 2011, this new infusion of capital will allow Soluble Therapeutics to accelerate the development and commercialization of the HSC Technology for protein formulation – a technology that is able to identify optimized formulations for protein-based therapeutics in 45 days while using minimal quantities of protein. This technology has the power to greatly reduce the time and resources required to prepare protein-based drugs for clinical development.

Dr. Larry DeLucas, Director of the UAB Center for Biophysical Sciences and Engineering is the principal investigator on the project and is one of the founding scientists of Soluble Therapeutics. Dr. Delucas states that he is “extremely pleased with the direction the company has taken with this technology and this Phase II award is proof of its commercial viability and immediate success in a challenging formulation market.”

“This grant is another testament to the excellent work in biotechnology that is coming out of Soluble Therapeutics, UAB and being fostered at Innovation Depot,” said Steven Ceulemans, Vice President of Innovation and Technology at the Birmingham Business Alliance, the Birmingham region’s leading economic development agency. “It demonstrates the value of the HSCTM Technology and the strength of the Birmingham region’s innovation infrastructure.”

Soluble Therapeutics’ CEO, Dr. Joseph Garner states that “our formulation service, utilizing the HSC Technology, continues to perform well in commercial engagements and this funding from the NIH further validates our technology as a new standard in protein formulation. We look forward to completing the development of the 3rd generation of the HSC Instrument that will be made available for purchase to the biopharmaceutical industry.”

About Soluble Therapeutics, Inc.

Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability, bringing transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSC Technology. For additional information visit www.soluble-therapeutics.com

John McCarter

Director of Business Development

205.314.3577 (p)

jnm@soluble-therapeutics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES